Ramification | Synthetic drugs, strategic risk: India's frontline in the global narcotics war

The world's drug problem used to have a geography. Heroin came from the poppy fields of Afghanistan, cocaine came from the coca plantations of Colombia, and cannabis grew where the climate allowed. For decades, drug enforcement meant controlling land, intercepting shipments at borders and pressuring governments to eradicate crops. The problem was vast and entrenched, but at the very least it was legible.

However, the world is witnessing the emergence of a new generation of synthetic narcotics that are cheaper to produce without climatic restraints and easier to traffick. These substances are collectively referred to as New Psychoactive Substances (NPS). The transition from agricultural drug production to laboratory-based manufacturing represents one of the most significant developments in international narcotics trafficking since the rise of methamphetamine in the late twentieth century.

More from Opinion

Unlike traditional narcotics that depend on specific geographic conditions for cultivation, synthetic drugs can be produced anywhere with access to precursor chemicals and basic laboratory equipment. This has resulted in criminal organisations shifting towards synthetic production models and creating a more decentralised global narcotics ecosystem. The United Nations Office on Drugs and Crime (UNODC) has identified synthetic drugs and new psychoactive substances as among the fastest-growing threats in the global drug market.

NPS are synthetic or semi-synthetic compounds designed to mimic the effects of controlled drugs while avoiding existing legal restrictions. As a result, thousands of new compounds have appeared over the last decade. By October 2025, UNODC had recorded nearly 1400 individual NPS worldwide. These included substances like synthetic cannabinoids, synthetic cathinones, novelopioids, designer benzodiazepines, dissociative drugs and hallucinogens. Telling us a story of the extraordinary pace of innovation within the illicit drug markets and consequently the constant challenge it creates for law enforcement agencies.

Among emerging narcotics, nitazenes represent perhaps the most dangerous development. Originally synthesised in the 1950s as potential pharmaceutical painkillers, they were abandoned because of their extreme addictiveness. They have now gone underground and have found illicit markets across North America, Europe, Australia, and other places. Nitazenes are often more potent than heroin and in some cases stronger than fentanyl. They are increasingly detected in counterfeit pharmaceuticals, heroin substitutes, cocaine mixtures and recreational drugs. Their potency makes accidental overdoses highly likely while standard toxicology screening frequently fails to detect them. For example, a hospital treating an overdose patient may run standard opioid tests, come back negative and miss the actual cause entirely. The strategic significance of nitazenes lies not merely in their lethality but in their economic efficiency. A small quantity can generate enormous profits while remaining easy to transport and conceal. This makes them highly attractive to transnational criminal organisations.

Synthetic cannabinoids constitute another rapidly growing category of narcotics. These substances are chemically engineered to imitate the effects of cannabis but produce far stronger and more unpredictable reactions. They are increasingly appearing in vaping products, edible products and herbal mixtures sold through illicit channels. Recent trends indicate growing availability of semi-synthetic cannabinoids such as THC derivatives manufactured through chemical processing rather than traditional cultivation. Because many users perceive these products as safer alternatives to conventional drugs. However, the consequences are severe. In Sierra Leone in 2024 mass burials had been conducted for dozens of young people killed by a synthetic cannabinoid known locally as "Kush". In New York City public health data showed at least nine synthetic cannabinoid overdose deaths from January 2024 to August 2025, with emergency department visits running well above historical norms.

While not new, methamphetamine also continues to evolve through increasingly industrialised production methods. Southeast Asia's Golden Triangle has become the world's largest synthetic drug-manufacturing hub producing unprecedented quantities of methamphetamine and related stimulants. Large-scale criminal enterprises now operate sophisticated production networks that resemble industrial manufacturing systems rather than traditional clandestine laboratories. These organisations exploit conflict zones and porous borders to maintain production.

According to a UNODC report released in May 2025, synthetic drug production and trafficking from the Golden Triangle have grown exponentially. Methamphetamine seizures across East and Southeast Asia reached 236 tonnes in 2024, which is a 24 per cent increase from the year before. Thailand alone seized one billion yaba tablets, methamphetamine pills, in 2024, while Cambodia recorded its largest methamphetamine seizure in history. The Indian Coast Guard intercepted the largest haul of methamphetamines in the Andaman and Nicobar Islands in 2024, valued at $4.3 billion. Myanmar's Shan State, where armed groups, criminal syndicates and corrupt officials operate in overlapping networks amid ongoing civil conflict, has emerged as the world's largest synthetic drug manufacturing zone.

For countries such as India the implications are particularly significant. The Golden Triangle remains a major source of methamphetamine and synthetic drugs entering South Asia. Simultaneously, the expansion of online drug markets and international precursor networks increases the possibility of domestic synthetic drug manufacturing. Emerging synthetic opioids could also create new public health crises similar to those witnessed in North America and Europe.

The emergence of these new narcotics requires a corresponding transformation in international responses. Governments must move beyond traditional eradication approaches toward enhanced chemical monitoring, forensic intelligence, cyber surveillance, international information sharing and public health preparedness. The struggle against narcotics is no longer confined to fields of poppy and coca; it is increasingly being fought in supply chains and digital networks. The countries that adapt most rapidly to this reality will be best positioned to manage the evolving threats posed by the next generation of drugs.

India's anti-narcotics framework has matured considerably under the Ministry of Home Affairs (MHA). The four-tier NCORD mechanism, established in 2016 and strengthened in 2019, coordinates efforts from district to apex level while dedicated anti-narcotics task forces now operate in every state and union territory. Initiatives like the MANAS helpline, the NIDAAN portal for tracking offenders, canine detection squads and fast-track NDPS courts reflect a genuine institutional push toward Prime Minister Modi's goal of a drug-free India by 2047. Enforcement has translated into real outcomes, and major drug busts have led to quick convictions.

India has also extended this expertise abroad. NCB has partnered with the US DEA on joint operations, including ketamine lab busts, controlled deliveries and ephedrine/methamphetamine investigations targeting trafficking networks bound for Myanmar, while India assists foreign authorities and international organisations to harmonise global counter-narcotics measures.

However, no nation can solve this alone. The world needs synchronised real-time intelligence sharing between agencies like the Narcotics Control Bureau (NCB), Drug Enforcement Administration (DEA) and UNODC as well as unified pressure on source countries like China to enforce accountability. But what has been true since India declared war against drugs is that this is not a fight that can be fought half-heartedly. From the Home Minister Amit Shah's direct oversight of NCORD to the Narcotics Control Bureau's expanding international partnerships, India is demonstrating through action, not just intent, that it is prepared to serve as a frontline force against the global synthetic drug menace. But importantly, the challenge is transnational, and unless other nations follow India's example, criminal networks will continue to exploit the weakest links in the international enforcement chain.

(Rami Niranjan Desai is a scholar of India’s northeast region and the neighbourhood. She is a columnist and author and is presently a Distinguished Fellow at India Foundation, New Delhi. Views expressed are personal and solely those of the author.)